Skye Bioscience Inc.’s Post

The event will focus on the scientific rationale for Skye’s Nimacimab peripheral CB1 inhibitor, the clinical experience, and the Phase 2 study design for Nimacimab as a monotherapy and in combination with a GLP-1R agonist. Dosing for the Phase 2 trial is expected to begin in Q3 2024. Read the full article here: https://bit.ly/45XSWdZ

“We are honored to unite these world-class obesity experts as we continue to advance the clinical development of Nimacimab for the treatment of obesity,” said Punit Dhillon, Chief Executive Officer and Chairman of Skye. “Their extensive scientific and clinical expertise will be instrumental in providing strategic oversight to support Skye as we expand our operations. We look forward to leveraging their guidance as we prepare to progress Nimacimab into a Phase 2 trial this quarter.” Read the full article here: https://bit.ly/4czOJPT

Skye Bioscience, Inc. (Nasdaq: SKYE) today announced the appointment of Karen Smith, MD, Ph.D., MBA, LLM to its Board of Directors. Dr. Smith brings significant global biotech and biopharma leadership experience, complementing the Company’s operational and clinical expertise. Read the full article here: https://bit.ly/3LbCm0q

"We are pleased to be included in the Russell indexes, a widely recognized benchmark for small-cap stocks, which is a testament to Skye’s recent accomplishments,” said Kaitlyn Arsenault, CPA, CFO. Read the full article here: https://bit.ly/4cmCjLr

Skye concentrates strategy and clinical development on Nimacimab metabolic program and discontinues SBI-100 Ophthalmic Emulsion program. Phase 2 study of Nimacimab in obesity expected to start in Q3 2024.

On Wednesday June 5th, Skye Bioscience's CSO Chris Twitty will present an overview of the company and its programs in obesity and glaucoma at the Jefferies Global Healthcare Conference 2024. You can listen to the webcast here: https://lnkd.in/g86ERASA

On Monday May 13th, Skye Bioscience's CEO and Chair Punit Dhillon will present an overview of the company at the Citizens JMP Securities Life Sciences Conference 2024. Listen live at 11:30 am ET or to the recording afterwards by registering here: https://lnkd.in/gDSZSds4

Skye is limitless and we are excited to announce we are growing our team 🚀 We are looking for a Senior Clinical Research Scientist to join our R&D team to help develop, plan and execute clinical biomarker studies. This person will be reporting to our Chief Scientific Officer, Chris Twitty, and be responsible for reviewing, analyzing and presenting clinical trial data from metabolic studies. This is an exciting time to join our fast growing team. Use the link below to apply! https://lnkd.in/gxg4T-ky